Silvia Martini, Valentina Zuco, Monica Tortoreto, Stefano Percio, Elisa Campi, Rihan El Bezawy, . . . Nadia Zaffaroni. (2021). miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. MDPI AG.
Chicago Style (17th ed.) CitationSilvia Martini, et al. MiR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. MDPI AG, 2021.
MLA (9th ed.) CitationSilvia Martini, et al. MiR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. MDPI AG, 2021.
Warning: These citations may not always be 100% accurate.